HSG

Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.

Generation Lab is focused on enhancing human health through the development of biological age testing services. The company aims to create a test that accurately assesses an individual's biological age and associated disease risks, utilizing clinically applicable biological evidence. By providing clinical-grade longevity reports and health span data analysis, Generation Lab enables healthcare professionals to optimize specific health areas based on the latest genomic research. The goal is to empower individuals to live longer and healthier lives by gaining insights into their biological age progression.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

Lingyi Biology is a gene therapy company that uses a platform to validate the functionality of animal models of rare diseases. It is dedicated to sourcing innovation, with a focus on genetic rare diseases like metabolism, CNS, and ophthalmology. Lingyi Biology has a gene therapy and rare disease discovery, development, and industrialization team, as well as a rare disease animal model preparation and verification platform, to address the pain point of a lack of effective animal models for rare disease research and development.

Rhegen is engaged in the research and development of mRNA medicine and gene therapy, focusing on synthetic biology technologies to create innovative mRNA drugs and vaccines. The company specializes in platform technologies essential for nucleic acid therapeutics, including mRNA design, synthesis, and non-carrier delivery methods. Rhegen applies these advancements to drug research and development, targeting various clinical indications such as functional protein defects, cancer, and infectious diseases. With a commitment to enhancing drug synthesis and developing novel drug targets, Rhegen aims to contribute significantly to the field of therapeutics, emphasizing both market potential and clinical value.

GenAssist Therapeutics is a biotechnology company founded in July 2020 that specializes in developing gene therapy drugs using advanced base editing technology. The company focuses on addressing genetic diseases, particularly neuromuscular disorders such as Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA), for which effective treatments are currently lacking. By employing Targeted AID-based Mutagenesis (TAM) technology, GenAssist aims to precisely repair disease-causing genes in situ, offering the potential for permanent cures. The company possesses global intellectual property rights for its innovative approach, reflecting its commitment to advancing gene editing therapies across a range of genetic conditions.

Biosysen is a synthetic biology company specializing in software-based species design and biomanufacturing. The company utilizes software engineering principles to enhance the self-replication and scalability of biological systems, aiming to unlock the full productivity potential of the biological industry. Biosysen's primary offerings include a library of artificial species and related industrial pipelines tailored for specific applications. These products cater to various sectors, including food production, medical testing, daily chemicals, and protein drug development, thereby supporting innovation and efficiency in these industries.

Frontera Therapeutics is a company specializing in adeno-associated virus (AAV) gene therapy, focused on developing and commercializing cost-effective recombinant virus-based therapies. The company aims to create a scalable platform that produces high-quality, affordable rAAV therapies for a range of genetic disorders, including ophthalmic, liver, metabolic, and neuromuscular diseases. Frontera Therapeutics has a diverse product pipeline that encompasses multiple therapeutic areas, with various candidates at different stages of development. By prioritizing affordability and quality, the company seeks to enhance the lives of patients through innovative genetic therapies.

NuProbe, Inc. is a genomics and molecular diagnostics company that focuses on noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in Shanghai, China, NuProbe has developed a platform that utilizes genetic toehold probes for quantitative PCR mutation detection. The company's innovative technology offers a Sample-In Answer-Out (SIAO) solution, which seamlessly integrates cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatic interpretation. This precision diagnostic technology is designed to facilitate the early detection of cancer and infectious diseases by accurately capturing disease signatures with high sensitivity and multiplexing capability, allowing healthcare professionals to initiate timely interventions for patients.

Yueer is a genomics company driven by technology, with a number of revolutionary molecular detection technologies that can reduce the sequencing cost of all NGS platforms and the sensitivity of qPCR, Sanger, and nanopore sequencing. Yueer Gene collaborates with many partners to develop affordable, timely, and accurate genetic analysis tools in order to achieve precision medicine and improve patient outcomes.

Grit Science is a biotechnology company specializing in gene therapeutics, particularly focusing on the research and development of liver-related genes. The firm is dedicated to creating medical products and genetic treatments that address clinical needs and enhance human health. Through its innovative approach to biopharmaceutical technology, Grit Science aims to contribute significantly to the field of medicine by developing solutions that improve patient outcomes.

Lingyi Biology is a gene therapy company that uses a platform to validate the functionality of animal models of rare diseases. It is dedicated to sourcing innovation, with a focus on genetic rare diseases like metabolism, CNS, and ophthalmology. Lingyi Biology has a gene therapy and rare disease discovery, development, and industrialization team, as well as a rare disease animal model preparation and verification platform, to address the pain point of a lack of effective animal models for rare disease research and development.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.

Geneus develops and commercializes gene sequencers and reagents. The core of its technology is based on the characteristic current signal generated by the interaction of protein nanopores and nucleic acid bases, and it realizes single-molecule nucleic acid sequencing through an integrated chip system.

Biosysen is a synthetic biology company specializing in software-based species design and biomanufacturing. The company utilizes software engineering principles to enhance the self-replication and scalability of biological systems, aiming to unlock the full productivity potential of the biological industry. Biosysen's primary offerings include a library of artificial species and related industrial pipelines tailored for specific applications. These products cater to various sectors, including food production, medical testing, daily chemicals, and protein drug development, thereby supporting innovation and efficiency in these industries.

Analytical Biosciences focuses on the development of single-cell genome technologies to enhance the understanding and treatment of human diseases. By collaborating with medical research institutions, hospitals, and pharmaceutical companies, the company leverages single-cell genomics and bioinformatics to create detailed maps of diseases. This approach allows for large-scale systematic disease mapping and the mining of extensive data sets, which aids partners in identifying new therapeutic targets and formulating innovative treatment strategies. Analytical Biosciences employs high-resolution databases and advanced data analytics to facilitate the discovery and validation of novel cellular targets and biomarkers, ultimately contributing to the development of next-generation therapeutics and diagnostics.

EdiGene Inc. is a biotechnology company based in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts. Founded in 2015, EdiGene specializes in the development of advanced genome editing technologies aimed at addressing various genetic diseases and cancer. The company focuses on both ex vivo and in vivo gene-editing therapies, utilizing proprietary platforms for modifying genetic information in human cells. Their innovative approaches include gene knockout, knock-in, and targeted mutations, which facilitate the creation of safer and more effective gene therapies. EdiGene also supports pharmaceutical research by providing high-throughput genome screening and drug target analysis, enhancing drug discovery efforts in the industry. Through its commitment to translating genome editing into therapeutics, EdiGene aims to improve human health outcomes and advance scientific research.

Benchling, Inc. is a cloud-based informatics company that provides a comprehensive platform tailored for life sciences research and development. Its flagship offering allows scientists to design, share, and document experiments through an integrated interface, enhancing collaboration and efficiency. The platform includes Benchling Insights, which enables users to query and visualize structured data, and a Bioregistry system for managing biological entity registrations and inventory such as plasmids and cell strains. Benchling's solutions support a variety of applications, including antibodies, cell therapy, gene therapy, and vaccines, catering to the needs of scientists in biotech, pharmaceutical, academic, and government sectors. Founded in 2012 and headquartered in San Francisco, Benchling aims to streamline the research process from discovery to bioprocessing, facilitating critical R&D decisions with its unified software suite.

PackGene Biotech, LLC is a biotechnology company based in the United States that specializes in developing viral vectors for gene therapies. It primarily focuses on adeno-associated virus (AAV) vectors, offering comprehensive services that include vector design, cloning, and packaging. The company also provides solutions for mRNA, plasmid DNA, and lentiviral vectors. With an emphasis on early-stage drug discovery and preclinical development, PackGene Biotech supports researchers in the medical industry by delivering high-purity, high-titer, and high-infectivity vectors for clinical applications. Its capabilities enable scalable and cost-effective production, facilitating advancements in cell and gene therapy trials.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on xenotransplantation. The company aims to address the critical shortage of organ donors by utilizing advanced gene editing techniques to develop safe and effective cells, tissues, and organs for human transplantation. Their mission is to eliminate the waiting period associated with organ transplants, providing patients with access to life-saving organs. By harnessing cutting-edge genetic editing technology, Qihan Biotech seeks to create viable organs that can be transplanted into humans, thereby contributing to a solution for the global organ donor crisis.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

NuProbe, Inc. is a genomics and molecular diagnostics company that focuses on noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in Shanghai, China, NuProbe has developed a platform that utilizes genetic toehold probes for quantitative PCR mutation detection. The company's innovative technology offers a Sample-In Answer-Out (SIAO) solution, which seamlessly integrates cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatic interpretation. This precision diagnostic technology is designed to facilitate the early detection of cancer and infectious diseases by accurately capturing disease signatures with high sensitivity and multiplexing capability, allowing healthcare professionals to initiate timely interventions for patients.

Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.

PackGene Biotech, LLC is a biotechnology company based in the United States that specializes in developing viral vectors for gene therapies. It primarily focuses on adeno-associated virus (AAV) vectors, offering comprehensive services that include vector design, cloning, and packaging. The company also provides solutions for mRNA, plasmid DNA, and lentiviral vectors. With an emphasis on early-stage drug discovery and preclinical development, PackGene Biotech supports researchers in the medical industry by delivering high-purity, high-titer, and high-infectivity vectors for clinical applications. Its capabilities enable scalable and cost-effective production, facilitating advancements in cell and gene therapy trials.

EdiGene Inc. is a biotechnology company based in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts. Founded in 2015, EdiGene specializes in the development of advanced genome editing technologies aimed at addressing various genetic diseases and cancer. The company focuses on both ex vivo and in vivo gene-editing therapies, utilizing proprietary platforms for modifying genetic information in human cells. Their innovative approaches include gene knockout, knock-in, and targeted mutations, which facilitate the creation of safer and more effective gene therapies. EdiGene also supports pharmaceutical research by providing high-throughput genome screening and drug target analysis, enhancing drug discovery efforts in the industry. Through its commitment to translating genome editing into therapeutics, EdiGene aims to improve human health outcomes and advance scientific research.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

BGI is a biotechnology company specializing in genomics. It provides genome sequencing and genetic testing services to research institutions and healthcare professionals worldwide. The company's offerings include bioinformatics, multi-omics solutions, and related tools, catering to a diverse range of clients such as pharmaceutical companies and academic institutions. BGI's work has contributed significantly to genetic and genomic research, with notable collaborations including Eli Lilly and Company, Merck, Pfizer Inc., and the Bill & Melinda Gates Foundation.

ViGeneron GmbH specializes in developing gene therapies aimed at treating ophthalmic diseases, particularly those with significant unmet medical needs. Founded in 2017 and based in Starnberg, Germany, the company utilizes two proprietary adeno-associated virus (AAV) technology platforms. The first, vgAAV, enhances transduction efficiency and allows for less invasive intravitreal treatment administration. The second platform, REVeRT, addresses diseases linked to mutations in large genes. ViGeneron's innovative approach aims to generate full-length proteins with high precision, facilitating the advancement of novel therapies for retinal disorders. The company also seeks partnerships with leading biopharmaceutical firms to expand its impact in other disease areas.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on xenotransplantation. The company aims to address the critical shortage of organ donors by utilizing advanced gene editing techniques to develop safe and effective cells, tissues, and organs for human transplantation. Their mission is to eliminate the waiting period associated with organ transplants, providing patients with access to life-saving organs. By harnessing cutting-edge genetic editing technology, Qihan Biotech seeks to create viable organs that can be transplanted into humans, thereby contributing to a solution for the global organ donor crisis.

Burning Rock Biotech Limited specializes in developing and providing cancer therapy selection tests in the People's Republic of China. The company offers a range of next-generation sequencing-based tests applicable to various cancer types, including lung, gastrointestinal, prostate, breast, and others, using tissue and liquid biopsy samples. Its key products include OncoScreen Plus for therapy and immunotherapy guidance, LungPlasma for non-small cell lung cancer, ColonCore for gastrointestinal cancers, and HRDCore for homologous recombination deficiency testing. Burning Rock collaborates with major pharmaceutical companies like AstraZeneca and BeiGene for clinical trials and research studies, primarily through central laboratory and companion diagnostics services. Founded in 2014, the company is headquartered in Guangzhou, with a focus on providing individualized cancer treatment guidance using NGS and biomedical informatics.

BrightGene Bio-Medical Technology Company is a biopharmaceutical firm based in Suzhou, China, specializing in the research, development, manufacturing, and commercialization of innovative medicines and high-quality generic active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). The company has a diverse product pipeline that includes immuno-oncological agents, GLP-1 receptor agonists for type 2 diabetes, and antibody-drug conjugates aimed at treating solid tumors and brain cancers. Additionally, BrightGene develops a variety of treatments such as Eribulin, Trabectedin, and various macromolecules and cytotoxic payloads. Its product offerings span multiple therapeutic areas, including oncology, cardiology, infectious diseases, and immunology. Founded in 2001, BrightGene has positioned itself as a leader in small molecules and nucleotide drugs, focusing on advancing therapeutics across all stages of development.

Geneception is a company focused on the development of breakthrough in gene and cell therapies that are fully-integrated.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on xenotransplantation. The company aims to address the critical shortage of organ donors by utilizing advanced gene editing techniques to develop safe and effective cells, tissues, and organs for human transplantation. Their mission is to eliminate the waiting period associated with organ transplants, providing patients with access to life-saving organs. By harnessing cutting-edge genetic editing technology, Qihan Biotech seeks to create viable organs that can be transplanted into humans, thereby contributing to a solution for the global organ donor crisis.

Refuge Biotechnologies, Inc. is a Menlo Park, California-based company focused on developing cancer immunotherapies through the application of synthetic biology and gene-editing technology, specifically CRISPR-dCas. Founded in 2015, Refuge aims to enhance cell therapies by creating innovative treatments that can sense their environment and modulate multiple genes simultaneously. This approach allows for more potent and targeted cancer therapies, moving beyond traditional single-target treatments. The company's research and development efforts are centered on advancing both cancer diagnostics and immunotherapies to improve patient outcomes in cancer care.

NuProbe, Inc. is a genomics and molecular diagnostics company that focuses on noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in Shanghai, China, NuProbe has developed a platform that utilizes genetic toehold probes for quantitative PCR mutation detection. The company's innovative technology offers a Sample-In Answer-Out (SIAO) solution, which seamlessly integrates cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatic interpretation. This precision diagnostic technology is designed to facilitate the early detection of cancer and infectious diseases by accurately capturing disease signatures with high sensitivity and multiplexing capability, allowing healthcare professionals to initiate timely interventions for patients.

Moderna, Inc. is a biotechnology company established in 2010 and headquartered in Cambridge, Massachusetts. The company specializes in developing therapeutics and vaccines using messenger RNA (mRNA) technology, which provides instructions for cells to produce proteins essential for various biological functions. Moderna has a diverse pipeline, with numerous programs targeting infectious diseases, immuno-oncology, rare diseases, and cardiovascular conditions. As of September 2024, it has 40 mRNA development candidates in clinical trials across multiple therapeutic areas. The company's mRNA technology gained significant recognition with the authorization of its COVID-19 vaccine in December 2020. Moderna maintains strategic alliances with various organizations, including major pharmaceutical companies and research institutions, to enhance its research and development efforts.

MedGenome is a company focused on advancing global health through its sequencing genomics-based diagnostics and research platform. This platform utilizes genomics technologies, bioinformatics, computing, and big data analytics to explore the genetic underpinnings of various diseases, including cancer, metabolic disorders, eye disorders, and rare diseases. MedGenome offers high-end genetic diagnostic tests across multiple categories such as immuno-oncology, infectious diseases, reproductive health, and rare diseases. By leveraging the genetic diversity of large populations, the company aims to provide valuable insights that support the healthcare industry in understanding diseases at both genetic and molecular levels.

BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. BridgeBio creates a bridge from advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible. BridgeBio's mission is to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases.

Burning Rock Biotech Limited specializes in developing and providing cancer therapy selection tests in the People's Republic of China. The company offers a range of next-generation sequencing-based tests applicable to various cancer types, including lung, gastrointestinal, prostate, breast, and others, using tissue and liquid biopsy samples. Its key products include OncoScreen Plus for therapy and immunotherapy guidance, LungPlasma for non-small cell lung cancer, ColonCore for gastrointestinal cancers, and HRDCore for homologous recombination deficiency testing. Burning Rock collaborates with major pharmaceutical companies like AstraZeneca and BeiGene for clinical trials and research studies, primarily through central laboratory and companion diagnostics services. Founded in 2014, the company is headquartered in Guangzhou, with a focus on providing individualized cancer treatment guidance using NGS and biomedical informatics.

Burning Rock Biotech Limited specializes in developing and providing cancer therapy selection tests in the People's Republic of China. The company offers a range of next-generation sequencing-based tests applicable to various cancer types, including lung, gastrointestinal, prostate, breast, and others, using tissue and liquid biopsy samples. Its key products include OncoScreen Plus for therapy and immunotherapy guidance, LungPlasma for non-small cell lung cancer, ColonCore for gastrointestinal cancers, and HRDCore for homologous recombination deficiency testing. Burning Rock collaborates with major pharmaceutical companies like AstraZeneca and BeiGene for clinical trials and research studies, primarily through central laboratory and companion diagnostics services. Founded in 2014, the company is headquartered in Guangzhou, with a focus on providing individualized cancer treatment guidance using NGS and biomedical informatics.

MedGenome is a company focused on advancing global health through its sequencing genomics-based diagnostics and research platform. This platform utilizes genomics technologies, bioinformatics, computing, and big data analytics to explore the genetic underpinnings of various diseases, including cancer, metabolic disorders, eye disorders, and rare diseases. MedGenome offers high-end genetic diagnostic tests across multiple categories such as immuno-oncology, infectious diseases, reproductive health, and rare diseases. By leveraging the genetic diversity of large populations, the company aims to provide valuable insights that support the healthcare industry in understanding diseases at both genetic and molecular levels.

Biomodal is a developer of DNA sequencing technology focused on advancing medicines, diagnostics, and personalized treatments. The company's innovative tools are designed to seamlessly integrate with existing sequencing and computing platforms. This integration allows for enhanced data extraction from DNA, enabling clients to obtain comprehensive genetic and epigenetic methylation information in a single workflow. By streamlining the sequencing process, Biomodal aims to improve the efficiency and effectiveness of genetic analysis, thereby supporting the development of tailored medical solutions.

BGI is a biotechnology company specializing in genomics. It provides genome sequencing and genetic testing services to research institutions and healthcare professionals worldwide. The company's offerings include bioinformatics, multi-omics solutions, and related tools, catering to a diverse range of clients such as pharmaceutical companies and academic institutions. BGI's work has contributed significantly to genetic and genomic research, with notable collaborations including Eli Lilly and Company, Merck, Pfizer Inc., and the Bill & Melinda Gates Foundation.